The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis
Open accessAbstract
The human oncoprotein MDM2 (hMDM2) overexpresses in various human tumors. If amplified, the mdm2 gene can enhance the tumorigenic potential of murine cells. Here, we present evidence to show that the full-length human or mouse MDM2 expressed from their respective cDNA can inhibit the G0/G1-S phase transition of NIH 3T3 and normal human diploid cells. The protein harbors more than one cell-cycle-inhibitory domain that does not overlap with the p53-interaction domain. Deletion mutants of hMDM2 that lack the cell-cycle-inhibitory domains can be stably expressed in NIH 3T3 cells, enhancing their tumorigenic potential. The tumorigenic domain of hMDM2 overlaps with the p53-interaction domain. Some tumor-derived cells, such as Saos-2, H1299 or U-2OS, are relatively insensitive to the growth-inhibitory effects of hMDM2. These observations suggest that hMDM2 overexpression in response to oncogenic stimuli would induce growth arrest in normal cells. Elimination or inactivation of the hMDM2-induced G0/G1 arrest may contribute to one of the steps of tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small increases in Mdm2 levels in normal cells are tolerated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Brown, et al., 1998
In the citing paper
“higher levels are incompatible with life in vivo and in vitro, except in some cases when p53 is also inactivated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Brown, et al., 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“A recent report (Serrano et al., 1997) has demonstrated that overexpression of oncogenic ras can induce G1 arrest of primary human and rodent cells.”
BackgroundCurrent Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,629
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
Cited by
Sorted by citations
Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 411
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152
(2003) · PubMed · Cited by 147
Lind, H., Zienolddiny, S., Ekstrøm, P. O., Skaug, V., & Haugen, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21872 · Cited by 144
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138
The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 138
Gazzéri, S., Della-Valle, V., Chaussade, L., Brambilla, C., Larsen, C., & Brambilla, E. M. (1998) · PubMed · Cited by 126
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 127
MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas
Balik, V., Srovnal, J., Sulla, I. J., Kalita, O., Foltánová, T., Vaverka, M., Hrabálek, L., & Hajdúch, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1038-6 · Cited by 126
Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells
Schwarze, S. R., DePrimo, S. E., Grabert, L. M., Fu, V. X., Brooks, J. D., & Jarrard, D. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200373200 · Cited by 119
Wienken, M., Dickmanns, A., Nemajerová, A., Kramer, D., Najafova, Z., Weiss, M., Karpiuk, O., Kassem, M. S., Zhang, Y., Lozano, G., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.12.008 · Cited by 116
DDB2 decides cell fate following DNA damage
Stoyanova, T., Roy, N., Kopanja, D., Bagchi, S., & Raychaudhuri, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812254106 · Cited by 108
Analysis of the degradation function of Mdm2.
Kubbutat, M. H. G., Ludwig, R., Levine, A. J., & Vousden, K. H. (1999) · PubMed · Cited by 102
Daujat, S., NEEL, H., & PIETTE, J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02369-1 · Cited by 97
Cell cycle regulatory functions of the human oncoprotein MDM2.
Deb, S. P. (2003) · PubMed · Cited by 96
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
Lu, W., Pochampally, R. R., Chen, L., Chomnawang, M. T., Wang, Y., & Chen, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203262 · Cited by 90
Dissociation of the recombination control and the sequence-specific transactivation function of P53
Dudenhöffer, C., Kurth, M., Janus, F., Deppert, W., & Wiesmüller, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202964 · Cited by 89
The RING domain of Mdm2 can inhibit cell proliferation.
Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., & Roussel, M. F. (2002) · PubMed · Cited by 86
p53 Activity Results in DNA Replication Fork Processivity
Klusmann, I., Rodewald, S., Müller, L., Friedrich, M., Wienken, M., Li, Y., Schulz‐Heddergott, R., & Dobbelstein, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.036 · Cited by 78
Tumor promotion by Mdm2 splice variants unable to bind p53.
Fridman, J. S., Hernando, E., Hemann, M. T., de Stanchina, E., Cordon‐Cardo, C., & Lowe, S. W. (2003) · PubMed · Cited by 82
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Dysregulated glycolysis as an oncogenic event
Mikawa, T., LLeonart, M. E., Takaori‐Kondo, A., Inagaki, N., Yokode, M., & Kondoh, H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1840-3 · Cited by 85
Scission of the p53-MDM2 Loop by Ribosomal Proteins
Zhou, X. Y., Liao, J.-M., Liao, W.-J., & Lu, H. (2012) · Genes & Cancer · doi:10.1177/1947601912455200 · Cited by 82
Wang, Y.-C., Lin, R.-K., Tan, Y. C., Chen, J.-T., Chen, C., & Wang, Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.139 · Cited by 77
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72
DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response
Stoyanova, T., Roy, N., Kopanja, D., Raychaudhuri, P., & Bagchi, S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10109 · Cited by 70
Seavey, S. E., Holubar, M. K., Saucedo, L. J., & Perry, M. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7590-7598.1999 · Cited by 69
Tsai, S.-C., Pasumarthi, K. B. S., Pajak, L., Franklin, M. T., Patton, B. L., Wang, H., Henzel, W. J., Stults, J. T., & Field, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3239 · Cited by 70
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 69
Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase
Giono, L. E., Resnick‐Silverman, L., Carvajal, L. A., Clair, S. S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.254 · Cited by 68
Wei, W., Jobling, W. A., Chen, W., Hahn, W. C., & Sedivy, J. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2859-2870.2003 · Cited by 68
Lindström, M. S., Deisenroth, C., & Zhang, Y. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3861 · Cited by 65
Total Synthesis of Chlorofusin, Its Seven Chromophore Diastereomers, and Key Partial Structures
Clark, R. C., Lee, S. Y., & Boger, D. L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8012819 · Cited by 67
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 66
MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis
Li, G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl047 · Cited by 63
Giono, L. E., & Manfredi, J. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01967-06 · Cited by 62
Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication
Klusmann, I., Wohlberedt, K., Magerhans, A., Teloni, F., Korbel, J. O., Altmeyer, M., & Dobbelstein, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809592115 · Cited by 65
Giglio, S., Mancini, F., Gentiletti, F., Sparaco, G., Felicioni, L., Barassi, F., Martella, C., Prodosmo, A., Iacovelli, S., Buttitta, F., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0450 · Cited by 58
Mdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 57
Mdm2 and MdmX as Regulators of Gene Expression
Biderman, L., Manley, J. L., & Prives, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912455331 · Cited by 58
MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination
Maguire, M., Nield, P. C., Devling, T., Jenkins, R. E., Park, B. K., Polański, R., Vlatković, N., & Boyd, M. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5271 · Cited by 53
Bartel, F., Harris, L. C., Würl, P., & Taubert, H. W. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.29.2.1 · Cited by 52
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation
Hallenborg, P., Feddersen, S., Francoz, S., Murano, I., Sundekilde, U. K., Petersen, R. K., Akimov, V., Olson, M. V., Lozano, G., Cinti, S., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.15 · Cited by 52
Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
van Leeuwen, I. M. M., Higgins, M., Campbell, J., McCarthy, A. R., Sachweh, M. C. C., Navarro, A. M., & Laín, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0904 · Cited by 45
Role of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
Analysis of the molecular species generated by mdm2 gene amplification in liposarcomas
Tamborini, E., Torre, G. D., Lavarino, C. E., Azzarelli, A., Carpinelli, P., Pierotti, M. A., & Pilotti, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1271 · Cited by 46
Mdm2 and Tumorigenesis: Evolving Theories and Unsolved Mysteries
Senturk, E., & Manfredi, J. J. (2012) · Genes & Cancer · doi:10.1177/1947601912457368 · Cited by 46
Function and dysfunction of the human oncoprotein MDM2
Deb, S. P. (2002) · Frontiers in bioscience · doi:10.2741/a723 · Cited by 45
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication
Singh, S., Vaughan, C. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87724 · Cited by 45
Yu, Z.-C., Huang, Y., & Shieh, S.-Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1173 · Cited by 44
Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2
Mikawa, T., Maruyama, T., Okamoto, K., Nakagama, H., LLeonart, M. E., Tsusaka, T., Hori, K., Murakami, I., Izumi, T., Takaori‐Kondo, A., et al. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201306149 · Cited by 45
MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change
Xu, H., Zhang, Z., Li, M., & Zhang, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059568 · Cited by 41
Clark, R. C., Lee, S. Y., Searcey, M., & Boger, D. L. (2009) · Natural Product Reports · doi:10.1039/b821676b · Cited by 42
Solution structure of the C4 zinc finger domain of HDM2
Yu, G. W., Allen, M. D., Andreeva, A. E., Fersht, A. R., & Bycroft, M. (2005) · Protein Science · doi:10.1110/ps.051927306 · Cited by 40
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G. Z., Garinis, G. A., Ioannides, T., et al. (2000) · Molecular Medicine · doi:10.1007/bf03402115 · Cited by 38
Identification of a CK2 phosphorylation site in mdm2.
Götz, C., Kartarius, S., Scholtes, P., Nastainczyk, W., & Montenarh, M. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00882.x · Cited by 39
MDM2 309 polymorphism is associated with missed abortion
Fang, Y., Kong, B., Yang, Q., Ma, D., & Qu, X. (2009) · Human Reproduction · doi:10.1093/humrep/dep044 · Cited by 39
Dobbelstein, M., & Levine, A. J. (2020) · Cancer Science · doi:10.1111/cas.14433 · Cited by 40
Kurokawa, K., Tanaka, T., & Kato, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202628 · Cited by 37
Frum, R. A., Singh, S. K., Vaughan, C. A., Mukhopadhyay, N. D., Grossman, S. R., Windle, B. E., Deb, S., & Deb, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt944 · Cited by 36
The contribution of the RING finger domain of MDM2 to cell cycle progression
Argentini, M., Barboule, N., & Wasylyk, B. (2000) · Oncogene · doi:10.1038/sj.onc.1203737 · Cited by 35
Wang, Y., Zheng, Z., Zhang, J., Wang, Y., Kong, R., Liu, J., Zhang, Y., Deng, H., Du, X., & Ke, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655597 · Cited by 36
Inhibitors of MDM2 and MDMX: A Structural Perspective
Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 32
Neel, H., Daujat, S., Piette, J., Thisse, C., & Thisse, B. (2000) · Differentiation · doi:10.1046/j.1432-0436.2000.660201.x · Cited by 31
mdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma
Taubert, H. W., Koehler, T., Meye, A., Bartel, F., Lautenschläger, C., Borchert, S., Bache, M., Schmidt, H., & Würl, P. (2000) · Molecular Medicine · doi:10.1007/bf03401934 · Cited by 30
Akkız, H., Sümbül, A. T., Bayram, S., Bekar, A., & Akgöllü, E. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.04.008 · Cited by 28
Overexpression of p21 and MDM2 characterizes serous borderline ovarian tumors
Palazzo, J., Monzon, F. A., BURKE, M., Hyslop, T., Dunton, C. J., Barusevicius, A., Capuzzi, D. M., & Kovatich, A. J. (2000) · Human Pathology · doi:10.1053/hupa.2000.7641 · Cited by 28
Dias, C. S., Liu, Y., Yau, A., Westrick, L., & Evans, S. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3013 · Cited by 27
Gangwar, R., & Mittal, R. D. (2010) · DNA and Cell Biology · doi:10.1089/dna.2009.0982 · Cited by 26
Polański, R., Maguire, M., Nield, P. C., Jenkins, R. E., Park, B. K., Krawczyńska, K., Devling, T., Ray‐Sinha, A., Rubbi, C. P., Vlatković, N., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr070 · Cited by 26
Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila
Folberg-Blum, A., Sapir, A., Shilo, B., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205305 · Cited by 26
MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Frum, R. A., Ramamoorthy, M., Mohanraj, L., Deb, S., & Deb, S. P. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0334 · Cited by 25
Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis
Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 25
Wildgruber, R., Reil, G., Drews, O., Parlar, H., & Görg, A. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200206)2:6 · Cited by 63
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Li, H., Dong, L., Jin, M.-J., Li, Q.-Y., Wang, X. Q., Jia, M., Song, J., Zhang, S., & Yuan, S. (2023) · Molecules · doi:10.3390/molecules28031141 · Cited by 25
Zhou, R., Frum, R. A., Deb, S., & Deb, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3755 · Cited by 24
Impact ofMDM2single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma
Nakashima, M., Kondo, S., Shimizu, Y., Wakisaka, N., Murono, S., Furukawa, M., & Yoshizaki, T. (2008) · Acta Oto-Laryngologica · doi:10.1080/00016480701724904 · Cited by 24
MDM2 Splice Variants and Their Therapeutic Implications
Harris, L. C. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332654 · Cited by 24
HDM2-Binding Partners: Interaction with Translation Elongation Factor EF1α
Frum, R. A., Busby, S. A., Ramamoorthy, M., Deb, S., Shabanowitz, J., Hunt, D. F., & Deb, S. P. (2007) · Journal of Proteome Research · doi:10.1021/pr060584p · Cited by 23
MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism
Polański, R., Warburton, H. E., Ray‐Sinha, A., Devling, T., Pakula, H., Rubbi, C. P., Vlatković, N., & Boyd, M. T. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.049 · Cited by 22
Alternative splicing ofMDM2 mRNA in lung carcinomas and lung cell lines
Weng, M.-W., Lai, J.-C., Hsu, C.-P., Yu, K.-Y., Chen, C., Lin, T.-S., Lai, W., Lee, H., & Ko, J. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20118 · Cited by 22
Sánchez‐Aguilera, A., García, J. F., Sánchez‐Beato, M., & Piris, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209282 · Cited by 21
The MDM2 Oncoprotein Promotes Apoptosis in p53-Deficient Human Medullary Thyroid Carcinoma Cells
Dilla, T., Velasco, J. A., Medina, D. L., Jf, G.-P., & Santisteban, P. (2000) · Endocrinology · doi:10.1210/endo.141.1.7265 · Cited by 23
Serous tumors of low malignant potential of the ovary-molecular pathology: part 2
Hauptmann, S., & Dietel, M. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280100435 · Cited by 21
Fussenegger, M., & Bailey, J. E. (2007) · Springer eBooks · doi:10.1007/978-0-585-37971-5_7 · Cited by 22
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
Ilic, V. K., Egorova, O., Tsang, E., Gatto, M., Wen, Y., Zhao, Y., & Sheng, Y. (2022) · Biomolecules · doi:10.3390/biom12050643 · Cited by 20
MDM2 SNP309 contributes to non‐small cell lung cancer survival in Chinese
Dong, J., Ren, B., Hu, Z., Chen, J., Hu, L., Dai, J., Jin, G., Xu, L., & Shen, H. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20727 · Cited by 20
Schuster, K., Fan, L., & Harris, L. C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0146 · Cited by 20
Fang, Y., Kong, B., Yang, Q., Ma, D., & Qu, X. (2011) · Human Reproduction · doi:10.1093/humrep/der017 · Cited by 20
Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women
Zając, A. E., Stachowiak, G., Pertyński, T., Romanowicz, H., Wilczyński, J. R., & Smolarz, B. (2013) · Polish Journal of Pathology · doi:10.5114/pjp.2012.32776 · Cited by 19
Thromboxane A2 modulates cisplatin-induced apoptosis through a Siva1-dependent mechanism
Iorio‐Morin, C., Germain, P., Roy, S. J., Génier, S., Labrecque, P., & Parent, J. L. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.11 · Cited by 19
MDM2 Overexpression, Activation of Signaling Networks, and Cell Proliferation
Deb, S. P., Singh, S., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_12 · Cited by 18
MicroRNA-26a targets the mdm2/p53 loop directly in response to liver regeneration
Zhou, J., Li, Z., Huang, Y., Ju, W., Wang, D., Zhu, X., & He, X. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4282 · Cited by 16
Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16
Shi, W., Meng, Z., Chen, Z., Hua, Y., Gao, H., Wang, P., Lin, J., Zhou, Z., Luo, J., & Liu, L. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1208-4 · Cited by 16
Abdel-Hamid, E. S., & Elmalahy, M. H. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-72 · Cited by 16
Metadata
- Authors
- Brown, D. R., Thomas, C. A., & Palit Deb, S.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- Brown, Doris R.
- Venue
- The EMBO Journal
- Published
- 1998-05-01
- Volume
- 17
- Issue
- 9
- Pages
- 2513-2525
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1170593
- OpenAlex
- W2014749419
- Cited by
- 148
- References
- 78
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 14
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA070712, CA70712)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, oncoprotein, cell cycle arrest, G0/G1 arrest, carcinogenesis, deletion mutants, NIH3T3 cells, cancer cell lines, oncogene overexpression, growth inhibition
- MeSH terms
- Animals, Cell Cycle, Cell Division, Cell Line, Cell Transformation, Neoplastic, Flow Cytometry, Gene Amplification, Humans, Neoplasm Proteins, Nuclear Proteins, Proto-Oncogene Proteins, Recombinant Proteins, Transfection, Resting Phase, Cell Cycle, G1 Phase, S Phase, Mutagenesis, Site-Directed, 3T3 Cells, Sequence Deletion, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
